Despite nine AOMs being currently approved for the treatment of obesity, limited clinical trial evidence in older adults predominantly focuses on incretin therapy with glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and tirzepatide)
Rather than aiming for individuals to commit to complete abstinence, these medications may allow for meaningful reductions in alcohol consumption, decreasing both the intensity and frequency of heavy drinking episodes
In isolation, the peptide chlorotoxin Cy5.5 had already been found to bind to ion channels on brain tumor cells, but not to normal human cells
doi: 10.1038/s41598-025-03757-3
Anti-doping tests using mass spectrometry can detect it within the windows described above
Another difference is indications